Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL

Last updated: September 11, 2021
Sponsor: Bnai Zion Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chronic Lymphocytic Leukemia

Leukemia

Platelet Disorders

Treatment

N/A

Clinical Study ID

NCT04862806
0214-20-BNZ
  • Ages > 18
  • All Genders

Study Summary

On behalf of the Israel CLL study group the investigators will evaluate the efficacy and safety of BNT162b2 mRNA Covid-19 Vaccine in patients with chronic lymphocytic leukemia

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of CLL was according to the IWCLL criteria
  • All patients received two 30-μg doses of BNT162b2, administered intramuscularly 3weeks apart. (Pfizer).

Exclusion

Exclusion Criteria:

  • previous covid19 virus infection

Study Design

Total Participants: 1000
Study Start date:
February 01, 2021
Estimated Completion Date:
March 31, 2022

Connect with a study center

  • Bnai Zion Medical Center

    Haifa, 31048
    Israel

    Active - Recruiting

  • Hematology Division, Chaim Sheba Medical Center

    Tel Aviv,
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.